Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Hangcheng Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1540-4764; OpenAlex author ID A5053645460. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper

Papers 12

  1. Smad4 regulates TGF-β1-mediated hedgehog activation to promote epithelial-to-mesenchymal transition in pancreatic cancer cells by suppressing Gli1 activity. Co-author DOI 10.1016/j.csbj.2024.03.010↗
  2. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. Co-author DOI 10.1016/j.intimp.2023.110709↗
  3. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor β signaling in SMAD4-dependent … First author DOI 10.1038/s41420-023-01661-1↗
  4. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… Co-author DOI 10.1038/s41419-022-04573-7↗
  5. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… Co-author DOI 10.1038/s41419-022-04705-z↗
  6. Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells. Co-author DOI 10.1038/s41420-022-00922-9↗
  7. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Co-author DOI 10.1007/s10565-020-09562-0↗
  8. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Co-author DOI 10.18632/aging.203301↗
  9. Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Co-author DOI 10.18632/aging.203575↗
  10. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Co-author DOI 10.18632/aging.203725↗
  11. Pharmacological Inhibition of STAT3 Attenuates Pancreatic Cancer Cell Invasion and Migration By Interacting with TGF-Β/Smad Signaling Co-author DOI 10.21203/rs.3.rs-1055773/v1↗
  12. The Anti-Dysenteric Drug Fraxetin Enhances Anti-Tumor Efficacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation Co-author DOI 10.21203/rs.3.rs-125318/v1↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongheng Bai · 11 shared papers, 2020–2024 · strength 1.61
  2. Yanyi Xiao · 8 shared papers, 2020–2022 · strength 1.05
  3. Yangyang Guo · 7 shared papers, 2020–2023 · strength 0.97
  4. Hengyue Zhu · 6 shared papers, 2020–2022 · strength 0.79
  5. Qiyu Zhang · 6 shared papers, 2020–2022 · strength 0.79
  6. Qinbo Chen · 3 shared papers, 2021–2023 · strength 0.45
  7. Jiawei Chen · 3 shared papers, 2021–2023 · strength 0.44
  8. Miaomiao Lin · 2 shared papers, 2022 · strength 0.30
  9. Yunfeng Shan · 2 shared papers, 2021 · strength 0.29
  10. Junjie Deng · 2 shared papers, 2020–2021 · strength 0.23
  11. Chunjing Lin · 1 shared paper, 2024 · strength 0.20
  12. Ni Xie · 1 shared paper, 2021 · strength 0.16
  13. Xuhui Fan · 1 shared paper, 2021 · strength 0.16
  14. Haotian Fu · 1 shared paper, 2021 · strength 0.16
  15. Xiangyang Lin · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.